Aug 6, 2020

Sanofi, GSK Pursue COVID-19 Vaccine Trials with $2.1B from “Warp Speed”

Posted by in categories: biotech/medical, government, health

Sanofi and GlaxoSmithKline (GSK) will be awarded up to $2.1 billion by the U.S. Departments of Health and Human Services (HHS) and Defense (DoD) toward development and manufacturing of the recombinant protein-based COVID-19 vaccine being produced by the companies, they and the U.S. government said.

HHS and DoD are providing the funding as part of Operation Warp Speed—the program through which President Donald Trump’s administration has committed the nation to delivering 300 million vaccine doses protecting against SARS-CoV-2 by January 2021.

“The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” HHS Secretary Alex Azar II stated.

Leave a reply